FDA.reportPublic FDA data

UMECLIDINIUM Pharmacologic Class Indexing

Class set ID
4d23965d-5d94-4a6d-9278-7756fe502eb8
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use Umeclidinium ELLIPTA safely and effectively. See full prescribing information for Umeclidinium ELLIPTA. Umeclidinium ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013Prasco Laboratories202511062
These highlights do not include all the information needed to use Umeclidinium and Vilanterol ELLIPTA safely and effectively. See full prescribing information for Umeclidinium and Vilanterol ELLIPTA. Umeclidinium and Vilanterol ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013Prasco Laboratories | GlaxoSmithKline LLC202411223
These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE ELLIPTA (umeclidinium inhalation powder), for oral inhalation use Initial U.S. Approval: 2013GlaxoSmithKline LLC2023121327
These highlights do not include all the information needed to use ANORO ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2013GlaxoSmithKline LLC2023060229
These highlights do not include all the information needed to use TRELEGY ELLIPTA safely and effectively. See full prescribing information for TRELEGY ELLIPTA. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2017GlaxoSmithKline LLC2023060214